Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Anti-Adhesion Product · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Investigational product group | EXPERIMENTAL | Anti-Adhesion Product was applied to the rectal stump and the incision line. Like in the control group, surgical measures to prevent adhesions were also taken, e.g. using minimum traumatizing surgical technique, using powder-free gloves. |
| Control group | NO_INTERVENTION | Only surgical measures to prevent adhesions were taken, e.g. using minimum traumatizing surgical technique, using powder-free gloves. No specific additional treatment was applied. |
| Name | Type | Description |
|---|---|---|
| Anti-Adhesion Product | BIOLOGICAL | Anti-Adhesion Product (AAP) is a biological two-component product of human origin. The components of AAP are lyophilized Anti-Adhesion Protein Concentrate (AAPC), containing fibrinogen, lyophilized Thrombin Concentrate (TC) and the respective diluents for the reconstitution of the components. |
Inclusion Criteria: * Written informed consent obtained from the subject or the subject's legally authorized representative prior to study entry * Male or female subjects \> 18 years of age * Subjects undergoing abdominal surgery with the possibility that a rectal stump would remain due to one or m...
Anti-Adhesion Product is an investigational monoclonal antibody being studied for the prevention of intraperitoneal adhesions, which are fibrous bands that can form between abdominal tissues and organs after surgery. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
Anti-Adhesion Product is being developed by Baxter International Inc., a company publicly traded under the ticker symbol BAX. The company is conducting clinical research to evaluate the safety and efficacy of this investigational product for the prevention of intraperitoneal adhesions.
Anti-Adhesion Product is in Phase 2 clinical development. It is an investigational product and has not been approved by regulatory authorities. A Phase 2 clinical trial has been completed to evaluate its safety and efficacy in preventing intraperitoneal adhesions.
Anti-Adhesion Product has one completed Phase 2 clinical trial registered as NCT00512356, titled 'Efficacy and Safety Study of Anti-Adhesion Product in the Prevention of Intraperitoneal Adhesions.' The trial enrolled 46 participants and was conducted in Denmark, Poland, and Sweden.
Anti-Adhesion Product is a monoclonal antibody, a type of biologic therapy that uses laboratory-made proteins to target specific molecules in the body. Its exact molecular target has not been disclosed, but it is being studied for its potential to prevent the formation of intraperitoneal adhesions.